অনুসন্ধান ফলাফলগুলি - Jacqulyne Robichaux

  • প্রদর্শন 1 - 14 ফলাফল এর 14
ফলাফল পরিমার্জন করুন
  1. 1
    Poziotinib for Patients With <i>HER2</i> Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial

    Poziotinib for Patients With <i>HER2</i> Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial অনুযায়ী Yasir Y. Elamin, Jacqulyne Robichaux, Brett W. Carter, Mehmet Altan, Don L. Gibbons, Frank V. Fossella, Vincent K. Lam, Anisha B. Patel, Marcelo V. Negrão, Xiuning Le, Frank E. Mott, Jianjun Zhang, Lei Feng, George R. Blumenschein, Anne S. Tsao, John V. Heymach

    প্রকাশিত 2021
    সম্পূর্ণ পাঠ পাওয়ার জন্য
    Artigo
    তালিকাভুক্ত করুন
    সংরক্ষণ করুন:
  2. 2
    Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype

    Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype অনুযায়ী Monique B. Nilsson, Jacqulyne Robichaux, Matthew H. Herynk, Tina Cascone, Xiuning Le, Yasir Y. Elamin, Sonia Patel, Fahao Zhang, Li Xu, Limei Hu, Lixia Diao, Li Shen, Junqin He, Xiaoxing Yu, Petros Nikolinakos, Pierre Saintigny, Bingliang Fang, Luc Girard, Jing Wang, John D. Minna, Ignacio I. Wistuba, John V. Heymach

    প্রকাশিত 2020
    সম্পূর্ণ পাঠ পাওয়ার জন্য সম্পূর্ণ পাঠ পাওয়ার জন্য
    Artigo
    তালিকাভুক্ত করুন
    সংরক্ষণ করুন:
  3. 3
    Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer

    Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer অনুযায়ী Roy S. Herbst, Thomas John, Christian Grohé, Jonathan W. Goldman, Terufumi Kato, К. К. Лактионов, Laura Bonanno, Marcello Tiseo, Margarita Majem, Manuel Dómine, Myung‐Ju Ahn, Dariusz M. Kowalski, M. Pérol, Virote Sriuranpong, Mustafa Özgüroğlu, Preetida J. Bhetariya, Aleksandra Markovets, Yuri Rukazenkov, Caitlin Muldoon, Jacqulyne Robichaux, Ryan J. Hartmaier, Masahiro Tsuboi, Yi‐Long Wu

    প্রকাশিত 2025
    সম্পূর্ণ পাঠ পাওয়ার জন্য
    Artigo
    তালিকাভুক্ত করুন
    সংরক্ষণ করুন:
  4. 4
    OA02.06 A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)

    OA02.06 A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC) অনুযায়ী John V. Heymach, Marcelo V. Negrão, Jacqulyne Robichaux, B. Carter, Ami Patel, Mehmet Altan, Don L. Gibbons, Frank V. Fossella, George R. Simon, Vincent K. Lam, George R. Blumenschein, Anne S. Tsao, Jonathan M. Kurie, Frank E. Mott, David W. Jenkins, David H. Mack, Lei Feng, Brent Roeck, Zane Yang, V. Papadimitrakopoulou, Yasir Y. Elamin

    প্রকাশিত 2018
    সম্পূর্ণ পাঠ পাওয়ার জন্য সম্পূর্ণ পাঠ পাওয়ার জন্য
    Artigo
    তালিকাভুক্ত করুন
    সংরক্ষণ করুন:
  5. 5
    A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

    A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components অনুযায়ী Monique B. Nilsson, Huiying Sun, Jacqulyne Robichaux, Matthias Pfeifer, Ultan McDermott, Jon Travers, Lixia Diao, Yuanxin Xi, Pan Tong, Li Shen, Mia Hofstad, Masanori Kawakami, Xiuning Le, Xi Liu, You-Hong Fan, Alissa Poteete, Limei Hu, Marcelo V. Negrão, Hai T. Tran, Ethan Dmitrovsky, David H. Peng, Don L. Gibbons, Jing Wang, John V. Heymach

    প্রকাশিত 2020
    সম্পূর্ণ পাঠ পাওয়ার জন্য
    Artigo
    তালিকাভুক্ত করুন
    সংরক্ষণ করুন:
  6. 6
    Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

    Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer অনুযায়ী Jacqulyne Robichaux, Yasir Y. Elamin, Zhi Tan, Brett W. Carter, Shuxing Zhang, Shengwu Liu, Shuai Li, Ting Chen, Alissa Poteete, Adriana Estrada‐Bernal, Anh T. Le, Anna Truini, Monique B. Nilsson, Huiying Sun, Emily Roarty, Sarah B. Goldberg, Julie R. Brahmer, Mehmet Altan, Charles Lu, Vassiliki A. Papadimitrakopoulou, Katerina Politi, Robert C. Doebele, Kwok‐Kin Wong, John V. Heymach

    প্রকাশিত 2018
    সম্পূর্ণ পাঠ পাওয়ার জন্য
    Artigo
    তালিকাভুক্ত করুন
    সংরক্ষণ করুন:
  7. 7
    Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i>-Mutant NSCLC

    Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i>-Mutant NSCLC অনুযায়ী Xiuning Le, Sonam Puri, Marcelo V. Negrão, Monique B. Nilsson, Jacqulyne Robichaux, Theresa A. Boyle, J. Kevin Hicks, Katherine L. Lovinger, Emily Roarty, Waree Rinsurongkawong, Ming Tang, Huiying Sun, Yasir Y. Elamin, Lara Lacerda, Jeff Lewis, Jack A. Roth, Stephen G. Swisher, J. Jack Lee, William N. William, Bonnie S. Glisson, Jianjun Zhang, Vassiliki A. Papadimitrakopoulou, Jhanelle E. Gray, John V. Heymach

    প্রকাশিত 2018
    সম্পূর্ণ পাঠ পাওয়ার জন্য
    Artigo
    তালিকাভুক্ত করুন
    সংরক্ষণ করুন:
  8. 8
    CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance

    CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance অনুযায়ী Monique B. Nilsson, Yan Yang, Simon Heeke, Sonia Patel, Alissa Poteete, Hibiki Udagawa, Yasir Y. Elamin, César A. Moran, Yukie Kashima, Thiruvengadam Arumugam, Xiaoxing Yu, Xiaoyang Ren, Lixia Diao, Li Shen, Qi Wang, Minying Zhang, Jacqulyne Robichaux, Chunhua Shi, Allyson N. Pfeil, Hai T. Tran, Don L. Gibbons, Jason Bock, Jing Wang, John D. Minna, Susumu Kobayashi, Xiuning Le, John V. Heymach

    প্রকাশিত 2023
    সম্পূর্ণ পাঠ পাওয়ার জন্য
    Artigo
    তালিকাভুক্ত করুন
    সংরক্ষণ করুন:
  9. 9
    Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations

    Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations অনুযায়ী Marcelo V. Negrão, Victoria M. Raymond, Richard B. Lanman, Jacqulyne Robichaux, Junqin He, Monique B. Nilsson, Patrick Kwok‐Shing Ng, Bianca Amador, Emily Roarty, Rebecca J. Nagy, Kimberly C. Banks, Viola W. Zhu, Chun Fai Ng, Young Kwang Chae, Jeffrey Clarke, Jeffrey A. Crawford, Funda Meric‐Bernstam, Sai‐Hong Ignatius Ou, David R. Gandara, John V. Heymach, Trever G. Bivona, Caroline E. McCoach

    প্রকাশিত 2020
    সম্পূর্ণ পাঠ পাওয়ার জন্য সম্পূর্ণ পাঠ পাওয়ার জন্য
    Artigo
    তালিকাভুক্ত করুন
    সংরক্ষণ করুন:
  10. 10
    Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

    Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity অনুযায়ী Yasir Y. Elamin, Jacqulyne Robichaux, Brett W. Carter, Mehmet Altan, Hai T. Tran, Don L. Gibbons, Simon Heeke, Frank V. Fossella, Vincent K. Lam, Xiuning Le, Marcelo V. Negrão, Monique B. Nilsson, Anisha B. Patel, R.S.K. Vijayan, Jason B. Cross, Jianjun Zhang, Lauren A. Byers, Charles Lu, Tina Cascone, Lei Feng, Rajyalakshmi Luthra, F. Anthony San Lucas, Geeta S. Mantha, Mark Routbort, George R. Blumenschein, Anne S. Tsao, John V. Heymach

    প্রকাশিত 2022
    সম্পূর্ণ পাঠ পাওয়ার জন্য সম্পূর্ণ পাঠ পাওয়ার জন্য
    Artigo
    তালিকাভুক্ত করুন
    সংরক্ষণ করুন:
  11. 11
    Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

    Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity অনুযায়ী Jacqulyne Robichaux, Yasir Y. Elamin, R.S.K. Vijayan, Monique B. Nilsson, Lemei Hu, Junqin He, Fahao Zhang, Marlese A. Pisegna, Alissa Poteete, Huiying Sun, Shuai Li, Ting Chen, Han Han, Marcelo V. Negrão, Jordi Rodón, Lixia Diao, Jing Wang, Xiuning Le, Funda Meric‐Bernstam, Mark Routbort, Brent Roeck, Zane Yang, Victoria M. Raymond, Richard B. Lanman, Garrett M. Frampton, Vincent A. Miller, Alexa B. Schrock, Lee A. Albacker, Kwok‐Kin Wong, Jason B. Cross, John V. Heymach

    প্রকাশিত 2019
    সম্পূর্ণ পাঠ পাওয়ার জন্য
    Artigo
    তালিকাভুক্ত করুন
    সংরক্ষণ করুন:
  12. 12
    Structure-based classification predicts drug response in EGFR-mutant NSCLC

    Structure-based classification predicts drug response in EGFR-mutant NSCLC অনুযায়ী Jacqulyne Robichaux, Xiuning Le, R.S.K. Vijayan, J. Kevin Hicks, Simon Heeke, Yasir Y. Elamin, Heather Lin, Hibiki Udagawa, Ferdinandos Skoulidis, Hai T. Tran, Susan Varghese, Junqin He, Fahao Zhang, Monique B. Nilsson, Lemei Hu, Alissa Poteete, Waree Rinsurongkawong, Xiaoshan Zhang, Chenghui Ren, Xiaoke Liu, Lingzhi Hong, Jianjun Zhang, Lixia Diao, Russell W. Madison, Alexa B. Schrock, Jennifer Saam, Victoria M. Raymond, Bingliang Fang, Jing Wang, Min Jin Ha, Jason B. Cross, Jhanelle E. Gray, John V. Heymach

    প্রকাশিত 2021
    সম্পূর্ণ পাঠ পাওয়ার জন্য সম্পূর্ণ পাঠ পাওয়ার জন্য
    Artigo
    তালিকাভুক্ত করুন
    সংরক্ষণ করুন:
  13. 13
    Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

    Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer অনুযায়ী Marcelo V. Negrão, Ferdinandos Skoulidis, Meagan Montesion, Katja Schulze, Ilze Bāra, Vincent K. Shen, Hao Xu, Sylvia Hu, Dawen Sui, Yasir Y. Elamin, Xiuning Le, Michael E. Goldberg, Karthikeyan Murugesan, Chang‐Jiun Wu, Jianhua Zhang, David S Barreto, Jacqulyne Robichaux, Alexandre Reuben, Tina Cascone, Carl M. Gay, K. G. Mitchell, Lingzhi Hong, Waree Rinsurongkawong, Jack A. Roth, Stephen G. Swisher, J. Jack Lee, Anne S. Tsao, Vassiliki A. Papadimitrakopoulou, Don L. Gibbons, Bonnie S. Glisson, Gaurav Singal, Vincent A. Miller, Brian M. Alexander, Garrett M. Frampton, Lee A. Albacker, David S. Shames, Jianjun Zhang, John V. Heymach

    প্রকাশিত 2021
    সম্পূর্ণ পাঠ পাওয়ার জন্য সম্পূর্ণ পাঠ পাওয়ার জন্য
    Artigo
    তালিকাভুক্ত করুন
    সংরক্ষণ করুন:
  14. 14
    Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target

    Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target অনুযায়ী Xiuning Le, Marcelo V. Negrão, Alexandre Reuben, Lorenzo Federico, Lixia Diao, Daniel J. McGrail, Monique B. Nilsson, Jacqulyne Robichaux, Irene Guijarro Munoz, Sonia Patel, Yasir Y. Elamin, You-Hong Fan, Won-Chul Lee, Edwin R. Parra, Luisa M. Solis Soto, Runzhe Chen, Jun Li, Tatiana V. Karpinets, Roohussaba Khairullah, Humam Kadara, Carmen Behrens, Boris Sepesi, Ruiping Wang, Mingrui Zhu, Linghua Wang, Ara A. Vaporciyan, Jack A. Roth, Stephen G. Swisher, Cara Haymaker, Jianhua Zhang, Jing Wang, Kwok‐Kin Wong, Lauren A. Byers, Chantale Bernatchez, Jianjun Zhang, Ignacio I. Wistuba, Don L. Gibbons, Esra A. Akbay, John V. Heymach

    প্রকাশিত 2020
    সম্পূর্ণ পাঠ পাওয়ার জন্য সম্পূর্ণ পাঠ পাওয়ার জন্য
    Artigo
    তালিকাভুক্ত করুন
    সংরক্ষণ করুন:

অনুসন্ধান সাধনীগুলি: